|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Clopidogrel#Use in Specific Populations]] |
| {{Clopidogrel}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Use in Specific Populations==
| |
| | |
| ====8.1 Pregnancy====
| |
| | |
| '''Pregnancy Category B'''
| |
| | |
| Reproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose, respectively, on a mg/m2 basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of a human response, Plavix should be used during pregnancy only if clearly needed.
| |
| | |
| ====8.3 Nursing Mothers====
| |
| | |
| Studies in rats have shown that clopidogrel and/or its metabolites are excreted in the milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from clopidogrel, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
| |
| | |
| ====8.4 Pediatric Use====
| |
| | |
| Safety and effectiveness in pediatric populations have not been established.
| |
| | |
| A randomized, placebo-controlled trial (CLARINET) did not demonstrate a clinical benefit of clopidogrel in neonates and infants with [[cyanotic congenital heart disease]] palliated with a systemic-to-pulmonary arterial shunt. Possible factors contributing to this outcome were the dose of clopidogrel, the concomitant administration of [[aspirin]] and the late initiation of therapy following shunt palliation. It cannot be ruled out that a trial with a different design would demonstrate a clinical benefit in this patient population.
| |
| | |
| ====8.5 Geriatric Use====
| |
| | |
| Of the total number of subjects in the CAPRIE and CURE controlled clinical studies, approximately 50% of patients treated with Plavix were 65 years of age and older, and 15% were 75 years and older. In COMMIT, approximately 58% of the patients treated with Plavix were 60 years and older, 26% of whom were 70 years and older.
| |
| | |
| The observed risk of bleeding events with Plavix plus aspirin versus placebo plus aspirin by age category is provided in Table 1 and Table 2 for the CURE and COMMIT trials, respectively [see Adverse Reactions (6.1)]. No dosage adjustment is necessary in elderly patients.
| |
| | |
| ====8.6 Renal Impairment====
| |
| | |
| Experience is limited in patients with severe and moderate renal impairment [see Clinical Pharmacology (12.2)].
| |
| | |
| ====8.7 Hepatic Impairment====
| |
| | |
| No dosage adjustment is necessary in patients with hepatic impairment [see Clinical Pharmacology (12.2)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB/SANOFI PHARMACEUTICALS PARTNERSHIP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |